Considering that AF and CHF are mutual risk factors, we designed a clinical trial based on the rationale that SGLT-2 inhibitors might be able to improve the clinical outcome of AF with DM by establishing the rhythm control of AF. The gene discussed is SLC5A2; the disease is atrial fibrillation.